Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Author(s): Koushal Billowria, Ghanshyam Das Gupta and Pooja A. Chawla*

DOI: 10.2174/1871520622666220523145609

DownloadDownload PDF Flyer Cite As
Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer

Page: [124 - 141] Pages: 18

  • * (Excluding Mailing and Handling)

Abstract

Background: Amivantamab was approved on May 21st, 2021, by United States food and drug administration with the brand name Rybervant, used particularly for adult patients with exon20 insertion of epithelial growth factor receptor with locally advanced metastatic non-small cell lung cancer.

Objective: In this review, we explain the non-small cell lung cancer and molecular distinctions between non-small cell lung cancer and small cell lung cancer. We also conclude numerous components of non-small cell lung cancer, which include signs and symptoms of Amivantamab in inhibiting the cancer cell growth, various clinical trials on Amivantamab, adverse effects, and the contraindications of Amivantamab.

Methods: A comprehensive literature search was conducted in the relevant databases like ScienceDirect, PubMed, ResearchGate, and Google Scholar to identify studies.

Conclusion: Amivantamab is a new bispecific antibody that targets non-small cell lung cancer through two different pathways, i.e., by binding to epithelial growth factor receptor and mesenchymal epithelial transition factor. Amivantamab gets tightly bound to Fcγ3R, and thus, mediates the macrophage and NK-cell for the killing of cancer cells. Biological treatment of Amivantamab shows effectiveness against the epithelial growth factor receptor Exon20 insertions according to the preclinical data of the animal model.

Keywords: Non-small cell lung cancer, small cell lung cancer, epidermal growth factor receptor, mesenchymal growth factor receptor, tyrosine kinase, lung cancer.

Graphical Abstract

[1]
Grond, S.; Zech, D.; Diefenbach, C.; Radbruch, L.; Lehmann, K.A. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain, 1996, 64(1), 107-114.
[http://dx.doi.org/10.1016/0304-3959(95)00076-3] [PMID: 8867252]
[2]
Brescia, F.J.; Adler, D.; Gray, G.; Ryan, M.A.; Cimino, J.; Mamtani, R. Hospitalized advanced cancer patients: a profile. J. Pain Symptom Manage., 1990, 5(4), 221-227.
[http://dx.doi.org/10.1016/0885-3924(90)90015-C] [PMID: 2384701]
[3]
Caraceni, A.; Portenoy, R.K. An international survey of can-cer pain characteristics and syndromes. Pain, 1999, 82(3), 263-274.
[http://dx.doi.org/10.1016/S0304-3959(99)00073-1] [PMID: 10488677]
[4]
Greenwald, H.P.; Bonica, J.J.; Bergner, M. The prevalence of pain in four cancers. Cancer, 1987, 60(10), 2563-2569.
[http://dx.doi.org/10.1002/1097-0142(19871115)60:10<2563:AID-CNCR2820601036>3.0.CO;2-L] [PMID: 2444328]
[5]
Coyle, N.; Adelhardt, J.; Foley, K.M.; Portenoy, R.K. Charac-ter of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J. Pain Symptom Manage., 1990, 5(2), 83-93.
[http://dx.doi.org/10.1016/S0885-3924(05)80021-1] [PMID: 2348092]
[6]
Ventafridda, V.; Ripamonti, C.; De Conno, F.; Tamburini, M.; Cassileth, B.R. Symptom prevalence and control during can-cer patients’ last days of life. J. Palliat. Care, 1990, 6(3), 7-11.
[http://dx.doi.org/10.1177/082585979000600303] [PMID: 1700099]
[7]
Miller, K.D.; Goding Sauer, A.; Ortiz, A.P.; Fedewa, S.A.; Pinheiro, P.S.; Tortolero-Luna, G.; Martinez-Tyson, D.; Jemal, A.; Siegel, R.L. Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J. Clin., 2018, 68(6), 425-445.
[http://dx.doi.org/10.3322/caac.21494] [PMID: 30285281]
[8]
Cokkinides, V.; Albano, J.; Samuels, A.; Ward, M.; Thum, J. American cancer society: Cancer facts and figures; American Cancer Society: Atlanta, 2005.
[9]
Brambilla, E.; Travis, W.D.; Colby, T.V.; Corrin, B.; Shimosato, Y. The new World Health Organization classifica-tion of lung tumours. Eur. Respir. J., 2001, 18(6), 1059-1068.
[http://dx.doi.org/10.1183/09031936.01.00275301] [PMID: 11829087]
[10]
Cai, B.; Zhou, Z-Y.; Xue, W.; Hazra, N.C.; Singh, M.; Mishra, D.; Brixner, D.; Oderda, G.; Biskupiak, J. Budget impact of capmatinib for adults with metastatic non-small cell lung can-cer harboring a MET exon 14 skipping mutation in the United States. J. Med. Econ., 2021, 24(1), 131-139.
[http://dx.doi.org/10.1080/13696998.2020.1867470] [PMID: 33397178]
[11]
Janssen-Heijnen, M.L.; Coebergh, J-W.W. The changing epi-demiology of lung cancer in Europe. Lung Cancer, 2003, 41(3), 245-258.
[http://dx.doi.org/10.1016/S0169-5002(03)00230-7] [PMID: 12928116]
[12]
Chen, Y.M. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. J. Chin. Med. Assoc., 2013, 76(5), 249-257.
[http://dx.doi.org/10.1016/j.jcma.2013.01.010] [PMID: 23683257]
[13]
Gazdar, A.F. Should we continue to use the term non-small-cell lung cancer? Ann. Oncol., 2010, 21(Suppl. 7), vii225-vii229.
[http://dx.doi.org/10.1093/annonc/mdq372] [PMID: 20943619]
[14]
Liaw, Y.P.; Huang, Y.C.; Lien, G.W. Patterns of lung cancer mortality in 23 countries: Application of the age-period-cohort model. BMC Public Health, 2005, 5, 22.
[http://dx.doi.org/10.1186/1471-2458-5-22] [PMID: 15748289]
[15]
Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A., Jr; Di Maria, M.V.; Veve, R.; Bremmes, R.M.; Barón, A.E.; Zeng, C.; Franklin, W.A. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol., 2003, 21(20), 3798-3807.
[http://dx.doi.org/10.1200/JCO.2003.11.069] [PMID: 12953099]
[16]
Shigematsu, H.; Gazdar, A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer, 2006, 118(2), 257-262.
[http://dx.doi.org/10.1002/ijc.21496] [PMID: 16231326]
[17]
Nakamura, H.; Saji, H.; Ogata, A.; Hosaka, M.; Hagiwara, M.; Kawasaki, N.; Kato, H. Correlation between encoded protein overexpression and copy number of the HER2 gene with sur-vival in non-small cell lung cancer. Int. J. Cancer, 2003, 103(1), 61-66.
[http://dx.doi.org/10.1002/ijc.10795] [PMID: 12455054]
[18]
Hirashima, N.; Takahashi, W.; Yoshii, S.; Yamane, T.; Ooi, A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod. Pathol., 2001, 14(6), 556-562.
[http://dx.doi.org/10.1038/modpathol.3880350] [PMID: 11406656]
[19]
Tatematsu, A.; Shimizu, J.; Murakami, Y.; Horio, Y.; Naka-mura, S.; Hida, T.; Mitsudomi, T.; Yatabe, Y. Epidermal growth factor receptor mutations in small cell lung cancer. Clin. Cancer Res., 2008, 14(19), 6092-6096.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0332] [PMID: 18829487]
[20]
Rodenhuis, S.; van de Wetering, M.L.; Mooi, W.J.; Evers, S.G.; van Zandwijk, N.; Bos, J.L. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocar-cinoma of the lung. N. Engl. J. Med., 1987, 317(15), 929-935.
[http://dx.doi.org/10.1056/NEJM198710083171504] [PMID: 3041218]
[21]
De Biasi, F.; Del Sal, G.; Hand, P.H. Evidence of enhancement of the ras oncogene protein product (p21) in a spectrum of human tumors. Int. J. Cancer, 1989, 43(3), 431-435.
[http://dx.doi.org/10.1002/ijc.2910430315] [PMID: 2784420]
[22]
Potiron, V.A.; Roche, J.; Drabkin, H.A. Semaphorins and their receptors in lung cancer. Cancer Lett., 2009, 273(1), 1-14.
[http://dx.doi.org/10.1016/j.canlet.2008.05.032] [PMID: 18625544]
[23]
Yousem, S.A.; Nikiforova, M.; Nikiforov, Y. The histo-pathology of BRAF-V600E-mutated lung adenocarcinoma. Am. J. Surg. Pathol., 2008, 32(9), 1317-1321.
[http://dx.doi.org/10.1097/PAS.0b013e31816597ca] [PMID: 18636014]
[24]
Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med., 2008, 359(13), 1367-1380.
[http://dx.doi.org/10.1056/NEJMra0802714] [PMID: 18815398]
[25]
Cappuzzo, F.; Jänne, P.A.; Skokan, M.; Finocchiaro, G.; Ros-si, E.; Ligorio, C.; Zucali, P.A.; Terracciano, L.; Toschi, L.; Roncalli, M.; Destro, A.; Incarbone, M.; Alloisio, M.; Santoro, A.; Varella-Garcia, M. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol., 2009, 20(2), 298-304.
[http://dx.doi.org/10.1093/annonc/mdn635] [PMID: 18836087]
[26]
Beau-Faller, M.; Ruppert, A-M.; Voegeli, A-C.; Neuville, A.; Meyer, N.; Guerin, E.; Legrain, M.; Mennecier, B.; Wihlm, J-M.; Massard, G.; Quoix, E.; Oudet, P.; Gaub, M.P. MET gene copy number in non-small cell lung cancer: molecular analy-sis in a targeted tyrosine kinase inhibitor naïve cohort. J. Thorac. Oncol., 2008, 3(4), 331-339.
[http://dx.doi.org/10.1097/JTO.0b013e318168d9d4] [PMID: 18379349]
[27]
Higashiyama, M.; Doi, O.; Kodama, K.; Yokouchi, H.; Ka-sugai, T.; Ishiguro, S.; Takami, K.; Nakayama, T.; Nishisho, I. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 pro-tein accumulation. Br. J. Cancer, 1997, 75(9), 1302-1308.
[http://dx.doi.org/10.1038/bjc.1997.221] [PMID: 9155050]
[28]
Dworakowska, D. Jassem, E.; Jassem, J.; Peters, B.; Dziadzi-uszko, R.Żylicz, M.; Jakóbkiewicz-Banecka, J.; Kobierska-Gulida, G.; Szymanowska, A.; Skokowski, J.; Roessner, A.; Schneider-Stock, R. MDM2 gene amplification: a new inde-pendent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer, 2004, 43(3), 285-295.
[http://dx.doi.org/10.1016/j.lungcan.2003.09.010] [PMID: 15165086]
[29]
Rusch, V.; Baselga, J.; Cordon-Cardo, C.; Orazem, J.; Zaman, M.; Hoda, S.; McIntosh, J.; Kurie, J.; Dmitrovsky, E. Differ-ential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res., 1993, 53(10)(Suppl.), 2379-2385.
[PMID: 7683573]
[30]
Franklin, W.A.; Veve, R.; Hirsch, F.R.; Helfrich, B.A.; Bunn, Jr, P. A Epidermal growth factor receptor family in lung cancer and premalignancy.In: Seminars in Oncology; Elsevier, 2002, pp. 3-14.
[31]
Herbst, R.S. Review of epidermal growth factor receptor biol-ogy. Int. J. Radiat. Oncol. *Biology* Phys., 2004, 59(2), S21-S26.
[32]
Fujino, S.; Enokibori, T.; Tezuka, N.; Asada, Y.; Inoue, S.; Kato, H.; Mori, A. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur. J. Cancer, 1996, 32A(12), 2070-2074.
[http://dx.doi.org/10.1016/S0959-8049(96)00243-2] [PMID: 9014747]
[33]
Zhang, P.; Gao, W.Y.; Turner, S.; Ducatman, B.S. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and poten-tiates the cisplatin effect in vitro. Mol. Cancer, 2003, 2(1), 1-9.
[http://dx.doi.org/10.1186/1476-4598-2-1] [PMID: 12537587]
[34]
Rikova, K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; Hu, Y.; Tan, Z.; Stokes, M.; Sullivan, L.; Mitchell, J.; Wetzel, R.; Macneill, J.; Ren, J.M.; Yuan, J.; Bakalarski, C.E.; Villen, J.; Kornhauser, J.M.; Smith, B.; Li, D.; Zhou, X.; Gygi, S.P.; Gu, T.L.; Po-lakiewicz, R.D.; Rush, J.; Comb, M.J. Global survey of phos-photyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131(6), 1190-1203.
[http://dx.doi.org/10.1016/j.cell.2007.11.025] [PMID: 18083107]
[35]
Johnson, F.M.; Krug, L.M.; Tran, H.T.; Shoaf, S.; Prieto, V.G.; Tamboli, P.; Peeples, B.; Patel, J.; Glisson, B.S. Phase I studies of imatinib mesylate combined with cisplatin and iri-notecan in patients with small cell lung carcinoma. Cancer, 2006, 106(2), 366-374.
[http://dx.doi.org/10.1002/cncr.21640] [PMID: 16342249]
[36]
Rossi, G.; Cavazza, A.; Marchioni, A.; Longo, L.; Migaldi, M.; Sartori, G.; Bigiani, N.; Schirosi, L.; Casali, C.; Morandi, U.; Facciolongo, N.; Maiorana, A.; Bavieri, M.; Fabbri, L.M.; Brambilla, E. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J. Clin. Oncol., 2005, 23(34), 8774-8785.
[http://dx.doi.org/10.1200/JCO.2005.02.8233] [PMID: 16314638]
[37]
Carbone, D.P.; Mitsudomi, T.; Chiba, I.; Piantadosi, S.; Ru-sch, V.; Nowak, J.A.; McIntire, D.; Slamon, D.; Gazdar, A.; Minna, J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mu-tations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest, 1994, 106(6)(Suppl.), 377S-381S.
[http://dx.doi.org/10.1378/chest.106.6_Supplement.377S] [PMID: 7988268]
[38]
Wistuba, I.I.; Berry, J.; Behrens, C.; Maitra, A.; Shivapurkar, N.; Milchgrub, S.; Mackay, B.; Minna, J.D.; Gazdar, A.F. Mo-lecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin. Cancer Res., 2000, 6(7), 2604-2610.
[PMID: 10914700]
[39]
Chiba, I.; Takahashi, T.; Nau, M.M.; D’Amico, D.; Curiel, D.T.; Mitsudomi, T.; Buchhagen, D.L.; Carbone, D.; Pian-tadosi, S.; Koga, H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 1990, 5(10), 1603-1610.
[PMID: 1979160]
[40]
Shimizu, E.; Zhao, M.; Shinohara, A.; Namikawa, O.; Ogura, T.; Masuda, N.; Takada, M.; Fukuoka, M.; Sone, S. Differen-tial expressions of cyclin A and the retinoblastoma gene product in histological subtypes of lung cancer cell lines. J. Cancer Res. Clin. Oncol., 1997, 123(10), 533-538.
[http://dx.doi.org/10.1007/s004320050101] [PMID: 9393586]
[41]
Salgia, R.; Skarin, A.T. Molecular abnormalities in lung can-cer. J. Clin. Oncol., 1998, 16(3), 1207-1217.
[http://dx.doi.org/10.1200/JCO.1998.16.3.1207] [PMID: 9508209]
[42]
Hensel, C.H.; Hsieh, C-L.; Gazdar, A.F.; Johnson, B.E.; Sakaguchi, A.Y.; Naylor, S.L.; Lee, W-H.; Lee, E.Y.P. Altered structure and expression of the human retinoblastoma sus-ceptibility gene in small cell lung cancer. Cancer Res., 1990, 50(10), 3067-3072.
[PMID: 2159370]
[43]
Hopwood, P.; Thatcher, N. Preliminary experience with quali-ty of life evaluation in patients with lung cancer. Oncology (Williston Park), 1990, 4(5), 158-162.
[PMID: 2166550]
[44]
Huhti, E.; Sutinen, S.; Reinilä, A.; Poukkula, A.; Saloheimo, M. Lung cancer in a defined geographical area: history and histological types. Thorax, 1980, 35(9), 660-667.
[http://dx.doi.org/10.1136/thx.35.9.660] [PMID: 6255625]
[45]
Berghmans, T.; Paesmans, M.; Sculier, J-P. Prognostic factors in stage III non-small cell lung cancer: a review of conven-tional, metabolic and new biological variables. Ther. Adv. Med. Oncol., 2011, 3(3), 127-138.
[http://dx.doi.org/10.1177/1758834011401951] [PMID: 21904576]
[46]
Gupta, R.C.; Purohit, S.D.; Sharma, M.P.; Bhardwaj, S. Prima-ry bronchogenic carcinoma: clinical profile of 279 cases from mid-west Rajasthan. Indian J. Chest Dis. Allied Sci., 1998, 40(2), 109-116.
[PMID: 9775568]
[47]
Martins, S.J.; Pereira, J.R. Clinical factors and prognosis in non-small cell lung cancer. Am. J. Clin. Oncol., 1999, 22(5), 453-457.
[http://dx.doi.org/10.1097/00000421-199910000-00006] [PMID: 10521057]
[48]
Hamilton, W.; Sharp, D. Diagnosis of lung cancer in primary care: a structured review. Fam. Pract., 2004, 21(6), 605-611.
[http://dx.doi.org/10.1093/fampra/cmh605] [PMID: 15520035]
[49]
Twycross, R.G. The terminal care of patients with lung can-cer. Postgrad. Med. J., 1973, 49(576), 732-737.
[http://dx.doi.org/10.1136/pgmj.49.576.732] [PMID: 4132166]
[50]
Medina, F.M.; Barrera, R.R.; Morales, J.F.; Echegoyen, R.C.; Chavarría, J.G.; Rebora, F.T. Primary lung cancer in Mexico city: a report of 1019 cases. Lung Cancer, 1996, 14(2-3), 185-193.
[http://dx.doi.org/10.1016/0169-5002(96)00545-4] [PMID: 8794402]
[51]
Portenoy, R.K.; Miransky, J.; Thaler, H.T.; Hornung, J.; Bian-chi, C.; Cibas-Kong, I.; Feldhamer, E.; Lewis, F.; Matamoros, I.; Sugar, M.Z. Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect. Cancer, 1992, 70(6), 1616-1624.
[http://dx.doi.org/10.1002/1097-0142(19920915)70:6<1616:AID-CNCR2820700630>3.0.CO;2-7] [PMID: 1516015]
[52]
Watson, P.N.; Evans, R.J. Intractable pain with lung cancer. Pain, 1987, 29(2), 163-173.
[http://dx.doi.org/10.1016/0304-3959(87)91033-5] [PMID: 3614955]
[53]
Potter, J.; Higginson, I.J. Pain experienced by lung cancer patients: a review of prevalence, causes and pathophysiology. Lung Cancer, 2004, 43(3), 247-257.
[http://dx.doi.org/10.1016/j.lungcan.2003.08.030] [PMID: 15165082]
[54]
Kuo, C-W.; Chen, Y-M.; Chao, J.Y.; Tsai, C.M.; Perng, R.P. Non-small cell lung cancer in very young and very old pa-tients. Chest, 2000, 117(2), 354-357.
[http://dx.doi.org/10.1378/chest.117.2.354] [PMID: 10669674]
[55]
Rajput, P.S.; Khan, S.R.; Singh, P.; Chawla, P.A. Treatment of small cell lung cancer with lurbinectedin: A review. Anticancer. Agents Med. Chem., 2021.
[PMID: 34229593]
[56]
Geddes, D.M. The natural history of lung cancer: a review based on rates of tumour growth. Br. J. Dis. Chest, 1979, 73(1), 1-17.
[http://dx.doi.org/10.1016/0007-0971(79)90002-0] [PMID: 435370]
[57]
Sun, S.; Schiller, J.H.; Gazdar, A.F. Lung cancer in never smokers--a different disease. Nat. Rev. Cancer, 2007, 7(10), 778-790.
[http://dx.doi.org/10.1038/nrc2190] [PMID: 17882278]
[58]
Khuder, S.A. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer, 2001, 31(2-3), 139-148.
[http://dx.doi.org/10.1016/S0169-5002(00)00181-1] [PMID: 11165392]
[59]
Wistuba, I.I.; Gazdar, A.F. Lung cancer preneoplasia. Annu. Rev. Pathol., 2006, 1, 331-348.
[http://dx.doi.org/10.1146/annurev.pathol.1.110304.100103] [PMID: 18039118]
[60]
Yatabe, Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev., 2010, 29(1), 23-36.
[http://dx.doi.org/10.1007/s10555-010-9205-8] [PMID: 20135199]
[61]
Yatabe, Y.; Mitsudomi, T.; Takahashi, T. TTF-1 expression in pulmonary adenocarcinomas. Am. J. Surg. Pathol., 2002, 26(6), 767-773.
[http://dx.doi.org/10.1097/00000478-200206000-00010] [PMID: 12023581]
[62]
Minna, J.D.; Roth, J.A.; Gazdar, A.F. Focus on lung cancer. Cancer Cell, 2002, 1(1), 49-52.
[http://dx.doi.org/10.1016/S1535-6108(02)00027-2] [PMID: 12086887]
[63]
Wistuba, I.I.; Gazdar, A.F.; Minna, J.D. Molecular genetics of small cell lung carcinoma. Seminars in oncology; Elsevier, 2001, pp. 3-13.
[64]
Breuer, R.H.; Postmus, P.E.; Smit, E.F. Molecular pathology of non-small-cell lung cancer. Respiration, 2005, 72(3), 313-330.
[http://dx.doi.org/10.1159/000085376] [PMID: 15942304]
[65]
Wu, M.; Yuan, Y.; Pan, Y-Y.; Zhang, Y. Combined gefitinib and pemetrexed overcome the acquired resistance to epider-mal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Mol. Med. Rep., 2014, 10(2), 931-938.
[http://dx.doi.org/10.3892/mmr.2014.2243] [PMID: 24840891]
[66]
Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Ga-briel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676), 1497-1500.
[http://dx.doi.org/10.1126/science.1099314] [PMID: 15118125]
[67]
Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; Mardis, E.; Kupfer, D.; Wilson, R.; Kris, M.; Varmus, H. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA, 2004, 101(36), 13306-13311.
[http://dx.doi.org/10.1073/pnas.0405220101] [PMID: 15329413]
[68]
Huang, S-F.; Liu, H-P.; Li, L-H.; Ku, Y-C.; Fu, Y-N.; Tsai, H-Y.; Chen, Y-T.; Lin, Y-F.; Chang, W-C.; Kuo, H-P.; Wu, Y.C.; Chen, Y.R.; Tsai, S.F. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Tai-wan. Clin. Cancer Res., 2004, 10(24), 8195-8203.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-1245] [PMID: 15623594]
[69]
Kosaka, T.; Yatabe, Y.; Endoh, H.; Kuwano, H.; Takahashi, T.; Mitsudomi, T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implica-tions. Cancer Res., 2004, 64(24), 8919-8923.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-2818] [PMID: 15604253]
[70]
Tokumo, M.; Toyooka, S.; Kiura, K.; Shigematsu, H.; Tomii, K.; Aoe, M.; Ichimura, K.; Tsuda, T.; Yano, M.; Tsukuda, K.; Tabata, M.; Ueoka, H.; Tanimoto, M.; Date, H.; Gazdar, A.F.; Shimizu, N. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res., 2005, 11(3), 1167-1173.
[PMID: 15709185]
[71]
Shigematsu, H.; Lin, L.; Takahashi, T.; Nomura, M.; Suzuki, M.; Wistuba, I.I.; Fong, K.M.; Lee, H.; Toyooka, S.; Shimizu, N.; Fujisawa, T.; Feng, Z.; Roth, J.A.; Herz, J.; Minna, J.D.; Gazdar, A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung can-cers. J. Natl. Cancer Inst., 2005, 97(5), 339-346.
[http://dx.doi.org/10.1093/jnci/dji055] [PMID: 15741570]
[72]
Shigematsu, H.; Takahashi, T.; Nomura, M.; Majmudar, K.; Suzuki, M.; Lee, H.; Wistuba, I.I.; Fong, K.M.; Toyooka, S.; Shimizu, N.; Fujisawa, T.; Minna, J.D.; Gazdar, A.F. Somatic mutations of the HER2 kinase domain in lung adenocarcino-mas. Cancer Res., 2005, 65(5), 1642-1646.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-4235] [PMID: 15753357]
[73]
Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Set-tleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350(21), 2129-2139.
[http://dx.doi.org/10.1056/NEJMoa040938] [PMID: 15118073]
[74]
Amann, J.; Kalyankrishna, S.; Massion, P.P.; Ohm, J.E.; Girard, L.; Shigematsu, H.; Peyton, M.; Juroske, D.; Huang, Y.; Stuart Salmon, J.; Kim, Y.H.; Pollack, J.R.; Yanagisawa, K.; Gazdar, A.; Minna, J.D.; Kurie, J.M.; Carbone, D.P. Aber-rant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res., 2005, 65(1), 226-235.
[PMID: 15665299]
[75]
Cappuzzo, F.; Hirsch, F.R.; Rossi, E.; Bartolini, S.; Ceresoli, G.L.; Bemis, L.; Haney, J.; Witta, S.; Danenberg, K.; Dome-nichini, I.; Ludovini, V.; Magrini, E.; Gregorc, V.; Doglioni, C.; Sidoni, A.; Tonato, M.; Franklin, W.A.; Crino, L.; Bunn, P.A., Jr; Varella-Garcia, M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst., 2005, 97(9), 643-655.
[http://dx.doi.org/10.1093/jnci/dji112] [PMID: 15870435]
[76]
Hirsch, F.R.; Varella-Garcia, M.; McCoy, J.; West, H.; Xavier, A.C.; Gumerlock, P.; Bunn, P.A., Jr; Franklin, W.A.; Crowley, J.; Gandara, D.R. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridiza-tion associates with increased sensitivity to gefitinib in pa-tients with bronchioloalveolar carcinoma subtypes: a South-west Oncology Group Study. J. Clin. Oncol., 2005, 23(28), 6838-6845.
[http://dx.doi.org/10.1200/JCO.2005.01.2823] [PMID: 15998906]
[77]
Tsao, M-S.; Sakurada, A.; Cutz, J-C.; Zhu, C-Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richard-son, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F.A. Erlotinib in lung cancer - molecular and clini-cal predictors of outcome. N. Engl. J. Med., 2005, 353(2), 133-144.
[http://dx.doi.org/10.1056/NEJMoa050736] [PMID: 16014883]
[78]
Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2005, 2(3)e73
[http://dx.doi.org/10.1371/journal.pmed.0020073] [PMID: 15737014]
[79]
Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Jänne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.; Tenen, D.G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2005, 352(8), 786-792.
[http://dx.doi.org/10.1056/NEJMoa044238] [PMID: 15728811]
[80]
Das, A.K.; Sato, M.; Story, M.D.; Peyton, M.; Graves, R.; Redpath, S.; Girard, L.; Gazdar, A.F.; Shay, J.W.; Minna, J.D.; Nirodi, C.S. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensi-tive to ionizing radiation. Cancer Res., 2006, 66(19), 9601-9608.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-2627] [PMID: 17018617]
[81]
Rachwal, W.J.; Bongiorno, P.F.; Orringer, M.B.; Whyte, R.I.; Ethier, S.P.; Beer, D.G. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcino-mas. Br. J. Cancer, 1995, 72(1), 56-64.
[http://dx.doi.org/10.1038/bjc.1995.277] [PMID: 7599067]
[82]
Kern, J.A.; Slebos, R.J.; Top, B.; Rodenhuis, S.; Lager, D.; Robinson, R.A.; Weiner, D.; Schwartz, D.A. C-erbB-2 expres-sion and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest., 1994, 93(2), 516-520.
[http://dx.doi.org/10.1172/JCI117001] [PMID: 7906694]
[83]
Brabender, J.; Danenberg, K.D.; Metzger, R.; Schneider, P.M.; Park, J.; Salonga, D.; Hölscher, A.H.; Danenberg, P.V. Epi-dermal growth factor receptor and HER2-neu mRNA expres-sion in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res., 2001, 7(7), 1850-1855.
[PMID: 11448895]
[84]
Stephens, P.; Hunter, C.; Bignell, G.; Edkins, S.; Davies, H.; Teague, J.; Stevens, C.; O’Meara, S.; Smith, R.; Parker, A.; Barthorpe, A.; Blow, M.; Brackenbury, L.; Butler, A.; Clarke, O.; Cole, J.; Dicks, E.; Dike, A.; Drozd, A.; Edwards, K.; Forbes, S.; Foster, R.; Gray, K.; Greenman, C.; Halliday, K.; Hills, K.; Kosmidou, V.; Lugg, R.; Menzies, A.; Perry, J.; Pet-ty, R.; Raine, K.; Ratford, L.; Shepherd, R.; Small, A.; Ste-phens, Y.; Tofts, C.; Varian, J.; West, S.; Widaa, S.; Yates, A.; Brasseur, F.; Cooper, C.S.; Flanagan, A.M.; Knowles, M.; Leung, S.Y.; Louis, D.N.; Looijenga, L.H.; Malkowicz, B.; Pierotti, M.A.; Teh, B.; Chenevix-Trench, G.; Weber, B.L.; Yuen, S.T.; Harris, G.; Goldstraw, P.; Nicholson, A.G.; Futre-al, P.A.; Wooster, R.; Stratton, M.R. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature, 2004, 431(7008), 525-526.
[http://dx.doi.org/10.1038/431525b] [PMID: 15457249]
[85]
Brose, M.S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A.; Roth, J.A.; Albelda, S.M.; Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, P.A.; Wooster, R.; Stratton, M.R.; Weber, B.L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 2002, 62(23), 6997-7000.
[PMID: 12460918]
[86]
Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S.M.; Riggins, G.J.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304(5670), 554.
[http://dx.doi.org/10.1126/science.1096502] [PMID: 15016963]
[87]
Cersosimo, R.J. Lung cancer: a review. Am. J. Health Syst. Pharm., 2002, 59(7), 611-642.
[http://dx.doi.org/10.1093/ajhp/59.7.611] [PMID: 11944603]
[88]
Shinoura, N.; Yamada, R.; Okamoto, K.; Nakamura, O.; Shitara, N. Local recurrence of metastatic brain tumor after stereotactic radiosurgery or surgery plus radiation. J. Neurooncol., 2002, 60(1), 71-77.
[http://dx.doi.org/10.1023/A:1020256721761] [PMID: 12416548]
[89]
Lowe, S.W.; Bodis, S.; McClatchey, A.; Remington, L.; Ruley, H.E.; Fisher, D.E.; Housman, D.E.; Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science, 1994, 266(5186), 807-810.
[http://dx.doi.org/10.1126/science.7973635] [PMID: 7973635]
[90]
Liu, L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 1989, 58(1), 351-375.
[http://dx.doi.org/10.1146/annurev.bi.58.070189.002031] [PMID: 2549853]
[91]
Hotta, K.; Matsuo, K.; Ueoka, H.; Kiura, K.; Tabata, M.; Tan-imoto, M. Meta-analysis of randomized clinical trials compar-ing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 2004, 22(19), 3852-3859.
[http://dx.doi.org/10.1200/JCO.2004.02.109] [PMID: 15326195]
[92]
Ardizzoni, A.; Boni, L.; Tiseo, M.; Fossella, F.V.; Schiller, J.H.; Paesmans, M.; Radosavljevic, D.; Paccagnella, A.; Zat-loukal, P.; Mazzanti, P.; Bisset, D.; Rosell, R. Cisplatin- ver-sus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient da-ta meta-analysis. J. Natl. Cancer Inst., 2007, 99(11), 847-857.
[http://dx.doi.org/10.1093/jnci/djk196] [PMID: 17551145]
[93]
Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) plus Car-boplatin and Paclitaxel as first-line treatment of ad-vanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 2007, 12(6), 713-718.
[http://dx.doi.org/10.1634/theoncologist.12-6-713] [PMID: 17602060]
[94]
Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355(24), 2542-2550.
[http://dx.doi.org/10.1056/NEJMoa061884] [PMID: 17167137]
[95]
Cho, J.Y.; Kim, J.H.; Lee, Y.H.; Chung, K.Y.; Kim, S.K.; Gong, S.J.; You, N.C.; Chung, H.C.; Roh, J.K.; Kim, B.S. Cor-relation between K-ras gene mutation and prognosis of pa-tients with nonsmall cell lung carcinoma. Cancer, 1997, 79(3), 462-467.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19970201)79:3<462:AID-CNCR6>3.0.CO;2-K] [PMID: 9028355]
[96]
Britten, R.A.; Liu, D.; Tessier, A.; Hutchison, M.J.; Murray, D. ERCC1 expression as a molecular marker of cisplatin re-sistance in human cervical tumor cells. Int. J. Cancer, 2000, 89(5), 453-457.
[http://dx.doi.org/10.1002/1097-0215(20000920)89:5<453:AID-IJC9>3.0.CO;2-E] [PMID: 11008208]
[97]
Cohen, S.M.; Lippard, S.J. Cisplatin: from DNA damage to cancer chemotherapy; , 2001, pp. 93-130.
[http://dx.doi.org/10.1016/S0079-6603(01)67026-0]
[98]
Kartalou, M.; Essigmann, J.M. Mechanisms of resistance to cisplatin. Mutat. Res., 2001, 478(1-2), 23-43.
[http://dx.doi.org/10.1016/S0027-5107(01)00141-5] [PMID: 11406167]
[99]
Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev., 2007, 33(1), 9-23.
[http://dx.doi.org/10.1016/j.ctrv.2006.09.006] [PMID: 17084534]
[100]
Perez, R.P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer, 1998, 34(10), 1535-1542.
[http://dx.doi.org/10.1016/S0959-8049(98)00227-5] [PMID: 9893624]
[101]
Niedner, H.; Christen, R.; Lin, X.; Kondo, A.; Howell, S.B. Identification of genes that mediate sensitivity to cisplatin. Mol. Pharmacol., 2001, 60(6), 1153-1160.
[http://dx.doi.org/10.1124/mol.60.6.1153] [PMID: 11723219]
[102]
Chang, A.Y.; Kim, K.; Glick, J.; Anderson, T.; Karp, D.; Johnson, D. Phase II study of taxol, merbarone, and piroxan-trone in stage IV non-small-cell lung cancer: The Eastern Co-operative Oncology Group Results. J. Natl. Cancer Inst., 1993, 85(5), 388-394.
[http://dx.doi.org/10.1093/jnci/85.5.388] [PMID: 8094467]
[103]
Murphy, W.K.; Fossella, F.V.; Winn, R.J.; Shin, D.M.; Hynes, H.E.; Gross, H.M.; Davilla, E.; Leimert, J.; Dhingra, H.; Raber, M.N. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 1993, 85(5), 384-388.
[http://dx.doi.org/10.1093/jnci/85.5.384] [PMID: 8094466]
[104]
Haldar, S.; Basu, A.; Croce, C.M. Bcl2 is the guardian of mi-crotubule integrity. Cancer Res., 1997, 57(2), 229-233.
[PMID: 9000560]
[105]
Hennequin, C.; Giocanti, N.; Favaudon, V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br. J. Cancer, 1995, 71(6), 1194-1198.
[http://dx.doi.org/10.1038/bjc.1995.232] [PMID: 7779710]
[106]
Wang, L.G.; Liu, X.M.; Kreis, W.; Budman, D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol., 1999, 44(5), 355-361.
[http://dx.doi.org/10.1007/s002800050989] [PMID: 10501907]
[107]
Ofir, R.; Seidman, R.; Rabinski, T.; Krup, M.; Yavelsky, V.; Weinstein, Y.; Wolfson, M. Taxol-induced apoptosis in hu-man SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ., 2002, 9(6), 636-642.
[http://dx.doi.org/10.1038/sj.cdd.4401012] [PMID: 12032672]
[108]
Park, S-J.; Wu, C-H.; Gordon, J.D.; Zhong, X.; Emami, A.; Safa, A.R. Taxol induces caspase-10-dependent apoptosis. J. Biol. Chem., 2004, 279(49), 51057-51067.
[http://dx.doi.org/10.1074/jbc.M406543200] [PMID: 15452117]
[109]
Lin, H.L.; Liu, T.Y.; Chau, G.Y.; Lui, W.Y.; Chi, C.W. Com-parison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer, 2000, 89(5), 983-994.
[http://dx.doi.org/10.1002/1097-0142(20000901)89:5<983:AID-CNCR7>3.0.CO;2-G] [PMID: 10964328]
[110]
Mason, K.A.; Hunter, N.R.; Milas, M.; Abbruzzese, J.L.; Mi-las, L. Docetaxel enhances tumor radioresponse in vivo. Clin. Cancer Res., 1997, 3(12 Pt 1), 2431-2438.
[PMID: 9815644]
[111]
Milas, L.; Milas, M.M.; Mason, K.A. Combination of taxanes with radiation: preclinical studies. Semin. Radiat. Oncol., 1999, 9(2)(Suppl. 1), 12-26.
[PMID: 10210536]
[112]
Mason, K.; Staab, A.; Hunter, N.; McBride, W.; Petersen, S.; Terry, N.; Milas, L. Enhancement of tumor radioresponse by docetaxel: Involvement of immune system. Int. J. Oncol., 2001, 18(3), 599-606.
[http://dx.doi.org/10.3892/ijo.18.3.599] [PMID: 11179493]
[113]
Lee, S.J.; Lee, H.S.; Choi, J.S.; Na, J.O.; Seo, K.H.; Oh, M.H.; Jou, S.S. Remarkable effect of gefitinib retreatment in a lung cancer patient with lepidic predominat adenocarcinoma who had experienced favorable results from initial treatment with gefitinib: a case report. J. Clin. Med. Res., 2012, 4(3), 216-220.
[http://dx.doi.org/10.4021/jocmr816e] [PMID: 22719810]
[114]
Meric, J-B.; Faivre, S.; Monnerat, C.; Adi Vago, N.; Le Cheva-lier, T.; Armand, J-P.; Raymond, E. [Zd 1839 “Iressa”] Bull. Cancer, 2000, 87(12), 873-876.
[PMID: 11174115]
[115]
Anderson, N.G.; Ahmad, T.; Chan, K.; Dobson, R.; Bundred, N.J. ZD1839 (Iressa), a novel epidermal growth factor recep-tor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer, 2001, 94(6), 774-782.
[http://dx.doi.org/10.1002/ijc.1557] [PMID: 11745477]
[116]
Baselga, J.; Rischin, D.; Ranson, M.; Calvert, H.; Raymond, E.; Kieback, D.G.; Kaye, S.B.; Gianni, L.; Harris, A.; Bjork, T.; Averbuch, S.D.; Feyereislova, A.; Swaisland, H.; Rojo, F.; Albanell, J. Phase I safety, pharmacokinetic, and pharmaco-dynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol., 2002, 20(21), 4292-4302.
[http://dx.doi.org/10.1200/JCO.2002.03.100] [PMID: 12409327]
[117]
Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J-Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga, J. Multi-institutional randomized phase II trial of ge-fitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial).(corrected) J. Clin. Oncol., 2003, 21(12), 2237-2246. http://dx.doi.org/10.1200/JCO.2003.10.038
[PMID: 12748244]
[118]
Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J., Jr; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K.S.; Cella, D.; Wolf, M.K.; Averbuch, S.D.; Ochs, J.J.; Kay, A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a ran-domized trial. JAMA, 2003, 290(16), 2149-2158.
[http://dx.doi.org/10.1001/jama.290.16.2149] [PMID: 14570950]
[119]
von Minckwitz, G.; Jonat, W.; Fasching, P.; du Bois, A.; Kleeberg, U.; Lück, H-J.; Kettner, E.; Hilfrich, J.; Eiermann, W.; Torode, J.; Schneeweiss, A. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res. Treat., 2005, 89(2), 165-172.
[http://dx.doi.org/10.1007/s10549-004-1720-2] [PMID: 15692759]
[120]
Schiff, B.A.; McMurphy, A.B.; Jasser, S.A.; Younes, M.N.; Doan, D.; Yigitbasi, O.G.; Kim, S.; Zhou, G.; Mandal, M.; Bekele, B.N.; Holsinger, F.C.; Sherman, S.I.; Yeung, S.C.; El-Naggar, A.K.; Myers, J.N. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thy-roid cancer. Clin. Cancer Res., 2004, 10(24), 8594-8602.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-0690] [PMID: 15623643]
[121]
Han, S-Y.; Zhao, M-B.; Zhuang, G-B.; Li, P-P. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Lung Cancer, 2012, 75(1), 30-37.
[http://dx.doi.org/10.1016/j.lungcan.2011.06.001] [PMID: 21757251]
[122]
Grigoriu, B.; Berghmans, T.; Meert, A-P. Management of EGFR mutated nonsmall cell lung carcinoma patients. Eur. Respir. J., 2015, 45(4), 1132-1141.
[http://dx.doi.org/10.1183/09031936.00156614] [PMID: 25700389]
[123]
Dhillon, S. Gefitinib: a review of its use in adults with ad-vanced non-small cell lung cancer. Target. Oncol., 2015, 10(1), 153-170.
[http://dx.doi.org/10.1007/s11523-015-0358-9] [PMID: 25637458]
[124]
Li, F.; Zhu, T.; Cao, B.; Wang, J.; Liang, L. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung can-cer with EGFR-TKI resistance. Eur. J. Cancer, 2017, 84, 184-192.
[http://dx.doi.org/10.1016/j.ejca.2017.07.037] [PMID: 28822888]
[125]
Wang, Y.; Schmid-Bindert, G.; Zhou, C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther. Adv. Med. Oncol., 2012, 4(1), 19-29.
[http://dx.doi.org/10.1177/1758834011427927] [PMID: 22229045]
[126]
Abera, M.B.; Kazanietz, M.G. Protein kinase Cα mediates erlotinib resistance in lung cancer cells. Mol. Pharmacol., 2015, 87(5), 832-841.
[http://dx.doi.org/10.1124/mol.115.097725] [PMID: 25724832]
[127]
Zhao, J.; Guerrero, A.; Kelnar, K.; Peltier, H.J.; Bader, A.G. Synergy between next generation EGFR tyrosine kinase inhib-itors and miR-34a in the inhibition of non-small cell lung can-cer. Lung Cancer, 2017, 108, 96-102.
[http://dx.doi.org/10.1016/j.lungcan.2017.02.020] [PMID: 28625657]
[128]
Jung, J-W.; Hwang, S-Y.; Hwang, J-S.; Oh, E-S.; Park, S.; Han, I-O. Ionising radiation induces changes associated with epi-thelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur. J. Cancer, 2007, 43(7), 1214-1224.
[http://dx.doi.org/10.1016/j.ejca.2007.01.034] [PMID: 17379505]
[129]
Wild-Bode, C.; Weller, M.; Rimner, A.; Dichgans, J.; Wick, W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblas-toma. Cancer Res., 2001, 61(6), 2744-2750.
[PMID: 11289157]
[130]
Camphausen, K.; Moses, M.A.; Beecken, W-D.; Khan, M.K.; Folkman, J.; O’Reilly, M.S. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res., 2001, 61(5), 2207-2211.
[PMID: 11280788]
[131]
Giaccone, G. Clinical impact of novel treatment strategies. Oncogene, 2002, 21(45), 6970-6981.
[http://dx.doi.org/10.1038/sj.onc.1205565] [PMID: 12362278]
[132]
Zhang, T.; Cui, G-B.; Zhang, J.; Zhang, F.; Zhou, Y-A.; Jiang, T.; Li, X-F. Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol. Rep., 2010, 24(6), 1683-1689.
[PMID: 21042768]
[133]
Abbruzzese, J.L.; Grunewald, R.; Weeks, E.A.; Gravel, D.; Adams, T.; Nowak, B.; Mineishi, S.; Tarassoff, P.; Satterlee, W.; Raber, M.N. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol., 1991, 9(3), 491-498.
[http://dx.doi.org/10.1200/JCO.1991.9.3.491] [PMID: 1999720]
[134]
Csoka, K.; Liliemark, J.; Larsson, R.; Nygren, P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin. Oncol., 1995, 22(4)(Suppl. 11), 47-53.
[PMID: 7481845]
[135]
Pollera, C.F.; Ceribelli, A.; Crecco, M.; Oliva, C.; Calabresi, F. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Invest. New Drugs, 1997, 15(2), 115-121.
[http://dx.doi.org/10.1023/A:1005817024382] [PMID: 9220290]
[136]
Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin., 2014, 64(1), 9-29.
[http://dx.doi.org/10.3322/caac.21208] [PMID: 24399786]
[137]
Vincent, A.; Herman, J.; Schulick, R.; Hruban, R.H.; Goggins, M. Pancreatic cancer. Lancet, 2011, 378(9791), 607-620.
[http://dx.doi.org/10.1016/S0140-6736(10)62307-0] [PMID: 21620466]
[138]
Páez, D.; Labonte, M.J.; Lenz, H-J. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol. Clin., 2012, 41(1), 189-209.
[http://dx.doi.org/10.1016/j.gtc.2011.12.004] [PMID: 22341258]
[139]
Heinemann, V. Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized tri-als.In: Seminars in Oncology; Elsevier, 2002, pp. 9-16.
[140]
Erten, C.; Demir, L.; Somali, I.; Alacacioglu, A.; Kucukzey-bek, Y.; Akyol, M.; Can, A.; Dirican, A.; Bayoglu, V.; Tarhan, M.O. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac. J. Cancer Prev., 2013, 14(6), 3711-3717.
[http://dx.doi.org/10.7314/APJCP.2013.14.6.3711] [PMID: 23886170]
[141]
Franchina, T.; Adamo, B.; Ricciardi, G.R.; Caristi, N.; Agosti-no, R.M.; Proto, C.; Adamo, V. Activity of pegylated liposo-mal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case re-ports. Cancer Biol. Ther., 2012, 13(7), 472-476.
[http://dx.doi.org/10.4161/cbt.19593] [PMID: 22526226]
[142]
Herrmann, R.; Bodoky, G.; Ruhstaller, T.; Glimelius, B.; Ba-jetta, E.; Schüller, J.; Saletti, P.; Bauer, J.; Figer, A.; Pestalozzi, B.; Köhne, C.H.; Mingrone, W.; Stemmer, S.M.; Tàmas, K.; Kornek, G.V.; Koeberle, D.; Cina, S.; Bernhard, J.; Dietrich, D.; Scheithauer, W. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a ran-domized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Coopera-tive Oncology Group. J. Clin. Oncol., 2007, 25(16), 2212-2217.
[http://dx.doi.org/10.1200/JCO.2006.09.0886] [PMID: 17538165]
[143]
Heinemann, V.; Quietzsch, D.; Gieseler, F.; Gonnermann, M.; Schönekäs, H.; Rost, A.; Neuhaus, H.; Haag, C.; Clemens, M.; Heinrich, B.; Vehling-Kaiser, U.; Fuchs, M.; Fleckenstein, D.; Gesierich, W.; Uthgenannt, D.; Einsele, H.; Holstege, A.; Hin-ke, A.; Schalhorn, A.; Wilkowski, R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol., 2006, 24(24), 3946-3952.
[http://dx.doi.org/10.1200/JCO.2005.05.1490] [PMID: 16921047]
[144]
Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25(15), 1960-1966.
[http://dx.doi.org/10.1200/JCO.2006.07.9525] [PMID: 17452677]
[145]
Ou, S-H.I. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lym-phoma kinase rearranged non-small cell lung cancer and be-yond. Drug Des. Devel. Ther., 2011, 5, 471-485.
[http://dx.doi.org/10.2147/DDDT.S19045] [PMID: 22162641]
[146]
Zou, H.Y.; Li, Q.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.J.; Kung, P-P.; Nambu, M.D.; Los, G.; Bender, S.L.; Mroczkowski, B.; Christensen, J.G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor effi-cacy through antiproliferative and antiangiogenic mechanisms. Cancer Res., 2007, 67(9), 4408-4417.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-4443] [PMID: 17483355]
[147]
Christensen, J.G.; Zou, H.Y.; Arango, M.E.; Li, Q.; Lee, J.H.; McDonnell, S.R.; Yamazaki, S.; Alton, G.R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther., 2007, 6(12 Pt 1), 3314-3322.
[http://dx.doi.org/10.1158/1535-7163.MCT-07-0365] [PMID: 18089725]
[148]
Yasuda, H.; de Figueiredo-Pontes, L.L.; Kobayashi, S.; Costa, D.B. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J. Thorac. Oncol., 2012, 7(7), 1086-1090.
[http://dx.doi.org/10.1097/JTO.0b013e3182570919] [PMID: 22617245]
[149]
Bergethon, K.; Shaw, A.T.; Ou, S-H.I.; Katayama, R.; Lovly, C.M.; McDonald, N.T.; Massion, P.P.; Siwak-Tapp, C.; Gon-zalez, A.; Fang, R.; Mark, E.J.; Batten, J.M.; Chen, H.; Wilner, K.D.; Kwak, E.L.; Clark, J.W.; Carbone, D.P.; Ji, H.; Engel-man, J.A.; Mino-Kenudson, M.; Pao, W.; Iafrate, A.J. ROS1 rearrangements define a unique molecular class of lung can-cers. J. Clin. Oncol., 2012, 30(8), 863-870.
[http://dx.doi.org/10.1200/JCO.2011.35.6345] [PMID: 22215748]
[150]
Johnson, T.R.; Tan, W.; Goulet, L.; Smith, E.B.; Yamazaki, S.; Walker, G.S.; O’Gorman, M.T.; Bedarida, G.; Zou, H.Y.; Christensen, J.G.; Nguyen, L.N.; Shen, Z.; Dalvie, D.; Bello, A.; Smith, B.J. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica, 2015, 45(1), 45-59.
[http://dx.doi.org/10.3109/00498254.2014.941964] [PMID: 25034009]
[151]
Frampton, J.E. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs, 2013, 73(18), 2031-2051.
[http://dx.doi.org/10.1007/s40265-013-0142-z] [PMID: 24288180]
[152]
Krikorian, A.; Breillout, F. Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid. Onkologie, 1991, 14(1), 7-12.
[PMID: 2057177]
[153]
Potier, P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin. Oncol., 1989, 16(2)(Suppl. 4), 2-4.
[PMID: 2540531]
[154]
Yokoyama, A. . Multi-institutional phase II study of navelbine (vinorelbine) in non-small-cell lung cancer. Am. Soc. Clin. Oncol., 1992, 957.
[155]
Binet, S.; Chaineau, E.; Fellous, A.; Lataste, H.; Krikorian, A.; Couzinier, J.P.; Meininger, V. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int. J. Cancer, 1990, 46(2), 262-266.
[http://dx.doi.org/10.1002/ijc.2910460220] [PMID: 2200754]
[156]
Cros, S.; Wright, M.; Morimoto, M.; Lataste, H.; Couzinier, J.P.; Krikorian, A. Experimental antitumor activity of Na-velbine. Semin. Oncol., 1989, 16(2)(Suppl. 4), 15-20.
[PMID: 2711203]
[157]
Rowinsky, E.K.; Onetto, N.; Canetta, R.M.; Arbuck, S.G. Taxol: the first of the taxanes, an important new class of anti-tumor agents. Semin. Oncol., 1992, 19(6), 646-662.
[PMID: 1361079]
[158]
Synold, T.W.; Dussault, I.; Forman, B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and ef-flux. Nat. Med., 2001, 7(5), 584-590.
[http://dx.doi.org/10.1038/87912] [PMID: 11329060]
[159]
ter Haar, E.; Kowalski, R.J.; Hamel, E.; Lin, C.M.; Longley, R.E.; Gunasekera, S.P.; Rosenkranz, H.S.; Day, B.W. Dis-codermolide, a cytotoxic marine agent that stabilizes microtu-bules more potently than taxol. Biochemistry, 1996, 35(1), 243-250.
[http://dx.doi.org/10.1021/bi9515127] [PMID: 8555181]
[160]
Gligorov, J.; Lotz, J.P. Preclinical pharmacology of the tax-anes: implications of the differences. Oncologist, 2004, 9(Suppl. 2), 3-8.
[http://dx.doi.org/10.1634/theoncologist.9-suppl_2-3] [PMID: 15161985]
[161]
Rosen-Carole, C.; Ito, S. Using Brexanolone for Postpartum Depression Must Account for Lactation. Matern. Child Health J., 2021, 25(7), 1007-1009.
[http://dx.doi.org/10.1007/s10995-021-03144-0] [PMID: 34019187]
[162]
A study of amivantamab and lazertinib combination therapy versus osimertinib in locally advanced or metastatic non-small cell lung cancer. Available from: https://ClinicalTrials.gov/show/NCT04487080
[163]
Eren, B.; Sar, M.; Oz, B.; Dincbas, F.H.O. MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas. Ann. Acad. Med. Singap., 2008, 37(1), 32-39.
[PMID: 18265895]
[164]
Cavaliere, A.; Sun, S.; Lee, S.; Bodner, J.; Li, Z.; Huang, Y.; Moores, S.L.; Marquez-Nostra, B. Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2021, 48(2), 383-394.
[http://dx.doi.org/10.1007/s00259-020-04978-6] [PMID: 32770372]
[165]
Food, U.; Administration, D. FDA approves first targeted therapy for subset of non-small cell lung cancer., 2021.
[166]
Rosenmayr-Templeton, L. Industry news update covering May 2021. Ther. Deliv., 2021, 12(9), 637-644.
[http://dx.doi.org/10.4155/tde-2021-0047]
[167]
Syed, Y.Y. Amivantamab: First Approval. Drugs, 2021, 81(11), 1349-1353.
[http://dx.doi.org/10.1007/s40265-021-01561-7] [PMID: 34292533]
[168]
Neijssen, J.; Cardoso, R.M.F.; Chevalier, K.M.; Wiegman, L.; Valerius, T.; Anderson, G.M.; Moores, S.L.; Schuurman, J.; Parren, P.W.H.I.; Strohl, W.R.; Chiu, M.L. Discovery of ami-vantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J. Biol. Chem., 2021.296100641
[http://dx.doi.org/10.1016/j.jbc.2021.100641] [PMID: 33839159]
[169]
Vijayaraghavan, S.; Lipfert, L.; Chevalier, K.; Bushey, B.S.; Henley, B.; Lenhart, R.; Sendecki, J.; Beqiri, M.; Millar, H.J.; Packman, K.; Lorenzi, M.V.; Laquerre, S.; Moores, S.L. Ami-vantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol. Cancer Ther., 2020, 19(10), 2044-2056.
[http://dx.doi.org/10.1158/1535-7163.MCT-20-0071] [PMID: 32747419]
[170]
Ye, L.; Chen, X.; Zhou, F. EGFR-mutant NSCLC: emerging novel drugs. Curr. Opin. Oncol., 2021, 33(1), 87-94.
[http://dx.doi.org/10.1097/CCO.0000000000000701] [PMID: 33122578]
[171]
Grugan, K.D.; Dorn, K.; Jarantow, S.W.; Bushey, B.S.; Pardi-nas, J.R.; Laquerre, S.; Moores, S.L.; Chiu, M.L. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells, MAbs; Taylor & Fran-cis, 2017, pp. 114-126.
[172]
Jarantow, S.W.; Bushey, B.S.; Pardinas, J.R.; Boakye, K.; Lacy, E.R.; Sanders, R.; Sepulveda, M.A.; Moores, S.L.; Chiu, M.L. Impact of cell-surface antigen expression on target en-gagement and function of an epidermal growth factor recep-tor× c-MET bispecific antibody. J. Biol. Chem., 2015, 290(41), 24689-24704.
[http://dx.doi.org/10.1074/jbc.M115.651653] [PMID: 26260789]
[173]
Wong, S-F. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther., 2005, 27(6), 684-694.
[http://dx.doi.org/10.1016/j.clinthera.2005.06.003] [PMID: 16117976]
[174]
Ramalingam, S.; Forster, J.; Naret, C.; Evans, T.; Sulecki, M.; Lu, H.; Teegarden, P.; Weber, M.R.; Belani, C.P. Dual inhibi-tion of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung can-cer (NSCLC): a phase I study. J. Thorac. Oncol., 2008, 3(3), 258-264.
[http://dx.doi.org/10.1097/JTO.0b013e3181653d1b] [PMID: 18317068]
[175]
Yun, J.; Lee, S-H.; Kim, S-Y.; Jeong, S-Y.; Kim, J-H.; Pyo, K-H.; Park, C-W.; Heo, S.G.; Yun, M.R.; Lim, S.; Lim, S.M.; Hong, M.H.; Kim, H.R.; Thayu, M.; Curtin, J.C.; Knoblauch, R.E.; Lorenzi, M.V.; Roshak, A.; Cho, B.C. Antitumor activity of amivantamab (JNJ-61186372), an EGFR–MET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven NSCLC. Cancer Discov., 2020, 10(8), 1194-1209.
[PMID: 32414908]
[176]
Wang, R.; Jaw, J.J.; Stutzman, N.C.; Zou, Z.; Sun, P.D. Natural killer cell-produced IFN-γ and TNF-α induce target cell cytol-ysis through up-regulation of ICAM-1. J. Leukoc. Biol., 2012, 91(2), 299-309.
[http://dx.doi.org/10.1189/jlb.0611308] [PMID: 22045868]
[177]
Satoh, M.; Iida, S.; Shitara, K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther., 2006, 6(11), 1161-1173.
[http://dx.doi.org/10.1517/14712598.6.11.1161] [PMID: 17049014]
[178]
Sabari, J.; Shu, C.; Park, K.; Leighl, N.; Mitchell, P.; Kim, S.; Lee, J.; Kim, D.; Viteri, S.; Spira, A. OA04. 04 amivantamab in post-platinum EGFR exon 20 insertion mutant non-small cell lung cancer. J. Thorac. Oncol., 2021, 16(3), S108-S109.
[http://dx.doi.org/10.1016/j.jtho.2021.01.284]
[179]
Park, K.; Haura, E.B.; Leighl, N.B.; Mitchell, P.; Shu, C.A.; Girard, N.; Viteri, S.; Han, J-Y.; Kim, S-W.; Lee, C.K.; Saba-ri, J.K.; Spira, A.I.; Yang, T-Y.; Kim, D-W.; Lee, K. Hy.; Sanborn, R.E.; Trigo, J.; Goto, K.; Lee, J.-S.; Yang, J.C-H.; Govindan, R.; Bauml, J.M.; Garrido, P.; Krebs, M.G.; Reckamp, K.L.; Xie, J.; Curtin, J.C.; Haddish-Berhane, N.; Roshak, A.; Millington, D.; Lorenzini, P.; Thayu, M.; Knoblauch, R.E.; Cho, B.C. Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I Study. J. Clin. Oncol., 2021, 39(30), 3391-3402.